BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
Newsfile Corp•13/10/2026•07:00 ET
0
Key Highlights
- ➤Olive Cell completes development, commercial-scale manufacturing, and self-affirmed U.S. GRAS process
- ➤BioHarvest’s GMP facility is ready to produce Olive Cell for future customers or partners
- ➤Olive Cell is now available for licensing and commercialization through BioHarvest’s CDMO business
- ➤Preclinical testing reduced liver-cell lipid accumulation up to 37% versus controls
- ➤Preclinical testing reduced collagen accumulation up to 50%, with dose-dependent activity
Expert Statements
Zaki Rakib, Chief Executive Officer and Executive Chairman of BioHarvest Sciences
“This Olive Cell milestone is important because it demonstrates the full power of our business model”
Zaki Rakib, Chief Executive Officer and Executive Chairman of BioHarvest Sciences
“We used our Botanical Synthesis technology to create a proprietary asset, scaled it to industrial manufacturing and completed the regulatory work required for commercialization. The asset is now ready to license, and our GMP manufacturing facility is ready to produce it for the right customer. This is the model we intend to repeat across our growing portfolio of proprietary assets.”
Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facility
Milestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization
Get started
Create a free account to read the full story.